Cohance Lifesciences Ltd.
•2026-08-21
PROS
- Company is almost debt free
- Promoters have been increasing their shareholding - up 7.4pp over 2 years
- Company has a healthy return on capital (ROCE) of 23.9%
- Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.17x)
- Working capital cycle has improved - days down from 384 to 165
- Company comfortably covers its interest (44.9x coverage)
CONS
- Receivables are growing faster than sales - a possible quality concern
- Recent results are weak - TTM profit is down 48.5% versus prior year
- Total debt has risen sharply - up 81.4% year on year
- Operating margins have contracted to 33.2% from 58.3%
- Company has delivered a poor profit growth of 0.1% over past five years
- Stock is trading at 12.8x its book value
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | SUNPHARMA | 1898.00 | 37.65 | 455393.78 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| 2. | DIVISLAB | 8525.00 | 77.37 | 226311.96 | 0.35 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| 3. | TORNTPHARM | 5013.00 | 87.43 | 190678.41 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| 4. | CIPLA | 1416.00 | 33.94 | 114392.01 | 0.92 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| 5. | ZYDUSLIFE | 1105.00 | 24.42 | 110224.17 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| 6. | LUPIN | 2220.00 | 18.36 | 101506.15 | 0.81 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| 7. | MANKIND | 2391.00 | 48.34 | 98747.34 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| 8. | DRREDDY | 1171.00 | 30.33 | 97740.54 | 0.68 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| 9. | LAURUSLABS | 1807.00 | 89.30 | 97634.42 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| 10. | AUROPHARMA | 1615.15 | 25.03 | 92932.16 | 0.25 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| 11. | BIOCON | 414.30 | 136.32 | 67518.23 | 0.12 | 136.80 | 53.36 | 4336.00 | 10.89 | 3.26 | 19.54 |
| 12. | COHANCE | 447.60 | 161.21 | 17125.06 | 0.00 | -451.90 | -1073.92 | 4222.60 | 668.71 | 18.44 | 0.27 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 344 | 225 | 213 | 253 | 488 | 594 | 653 | 769 | 484 | 498 | 482 | 568 | 3,599 | |
| 173 | 127 | 144 | 180 | 363 | 391 | 421 | 546 | 379 | 367 | 379 | 451 | 3,698 | |
| Operating Profit | — | — | — | — | — | — | — | — | — | — | — | — | — |
| OPM % | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Income | 10 | 14 | 14 | 17 | 19 | 16 | 21 | 8 | 13 | 26 | 6 | -1 | 122 |
| Interest | 2 | 1 | 2 | 2 | 10 | 9 | 10 | 7 | 7 | 5 | 5 | 5 | 21 |
| Depreciation | 11 | 11 | 11 | 17 | 31 | 35 | 38 | 43 | 31 | 31 | 33 | 38 | 343 |
| 168 | 101 | 70 | 71 | 103 | 175 | 206 | 166 | 71 | 121 | 65 | 56 | 22 | |
| Tax % | 25.86% | 25.69% | 24.66% | 24.87% | 26.82% | 20.65% | 25.33% | 25.86% | 26.00% | 21.89% | 27.72% | 38.77% | 36.20% |
| Net Profit | 124 | 75 | 52 | 53 | 75 | 139 | 154 | 123 | 53 | 94 | 47 | 35 | 14 |
| 5 | 3 | 2 | 2 | 2 | 4 | 4 | 3 | 1 | 2 | 1 | 1 | 0 | |
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 38 | 38 | 38 | 38 | 383 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Equity Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 38 | 38 | 38 | 38 | 383 |
| Reserves | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Promoter Pledge % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
- 344
- 173
- Operating Profit
- —
- OPM %
- —
- Other Income
- 10
- Interest
- 2
- Depreciation
- 11
- 168
- Tax %
- 25.86%
- Net Profit
- 124
- 5
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 225
- 127
- Operating Profit
- —
- OPM %
- —
- Other Income
- 14
- Interest
- 1
- Depreciation
- 11
- 101
- Tax %
- 25.69%
- Net Profit
- 75
- 3
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 213
- 144
- Operating Profit
- —
- OPM %
- —
- Other Income
- 14
- Interest
- 2
- Depreciation
- 11
- 70
- Tax %
- 24.66%
- Net Profit
- 52
- 2
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 253
- 180
- Operating Profit
- —
- OPM %
- —
- Other Income
- 17
- Interest
- 2
- Depreciation
- 17
- 71
- Tax %
- 24.87%
- Net Profit
- 53
- 2
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 488
- 363
- Operating Profit
- —
- OPM %
- —
- Other Income
- 19
- Interest
- 10
- Depreciation
- 31
- 103
- Tax %
- 26.82%
- Net Profit
- 75
- 2
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 594
- 391
- Operating Profit
- —
- OPM %
- —
- Other Income
- 16
- Interest
- 9
- Depreciation
- 35
- 175
- Tax %
- 20.65%
- Net Profit
- 139
- 4
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 653
- 421
- Operating Profit
- —
- OPM %
- —
- Other Income
- 21
- Interest
- 10
- Depreciation
- 38
- 206
- Tax %
- 25.33%
- Net Profit
- 154
- 4
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 769
- 546
- Operating Profit
- —
- OPM %
- —
- Other Income
- 8
- Interest
- 7
- Depreciation
- 43
- 166
- Tax %
- 25.86%
- Net Profit
- 123
- 3
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 25
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 484
- 379
- Operating Profit
- —
- OPM %
- —
- Other Income
- 13
- Interest
- 7
- Depreciation
- 31
- 71
- Tax %
- 26.00%
- Net Profit
- 53
- 1
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 498
- 367
- Operating Profit
- —
- OPM %
- —
- Other Income
- 26
- Interest
- 5
- Depreciation
- 31
- 121
- Tax %
- 21.89%
- Net Profit
- 94
- 2
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 482
- 379
- Operating Profit
- —
- OPM %
- —
- Other Income
- 6
- Interest
- 5
- Depreciation
- 33
- 65
- Tax %
- 27.72%
- Net Profit
- 47
- 1
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 568
- 451
- Operating Profit
- —
- OPM %
- —
- Other Income
- -1
- Interest
- 5
- Depreciation
- 38
- 56
- Tax %
- 38.77%
- Net Profit
- 35
- 1
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 38
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- 3,599
- 3,698
- Operating Profit
- —
- OPM %
- —
- Other Income
- 122
- Interest
- 21
- Depreciation
- 343
- 22
- Tax %
- 36.20%
- Net Profit
- 14
- 0
- Equity Capital
- 383
- Reserves
- 0
- Promoter Pledge %
- 0.00%
- Equity Capital
- 383
- Reserves
- 0
- Promoter Pledge %
- 0.00%
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 378 | 834 | 1,010 | 1,320 | 1,330 | 1,051 | 1,094 | 1,907 | |
| 206 | 449 | 567 | 738 | 739 | 645 | 731 | 1,567 | |
| Operating Profit | 172 | 403 | 457 | 770 | 635 | 462 | 417 | — |
| OPM % | 46 | 48 | 45 | 58 | 48 | 44 | 38 | — |
| Other Income | 1 | 18 | 14 | 188 | 45 | 57 | 54 | 44 |
| Interest | 3 | 22 | 12 | 9 | 13 | 7 | 8 | 18 |
| Depreciation | 11 | 24 | 32 | 39 | 43 | 55 | 57 | 137 |
| 158 | 358 | 414 | 722 | 579 | 400 | 351 | 245 | |
| Tax % | 31 | 24 | 25 | 23 | 25 | 26 | 23 | 27 |
| Net Profit | 109 | 270 | 309 | 558 | 433 | 296 | 272 | 178 |
| EPS | 0 | 11 | 12 | 22 | 17 | 12 | 11 | — |
| Dividend Payout % | — | 24 | 16 | 23 | 35 | 0 | 0 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 0 | 11 | 12 | 22 | 17 | 12 | 11 | — |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share of Associates | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adjusted EPS | 0 | 11 | 12 | 22 | 17 | 12 | 11 | — |
- 378
- 206
- Operating Profit
- 172
- OPM %
- 46
- Other Income
- 1
- Interest
- 3
- Depreciation
- 11
- 158
- Tax %
- 31
- Net Profit
- 109
- EPS
- 0
- Dividend Payout %
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 0
- 834
- 449
- Operating Profit
- 403
- OPM %
- 48
- Other Income
- 18
- Interest
- 22
- Depreciation
- 24
- 358
- Tax %
- 24
- Net Profit
- 270
- EPS
- 11
- Dividend Payout %
- 24
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
- 1,010
- 567
- Operating Profit
- 457
- OPM %
- 45
- Other Income
- 14
- Interest
- 12
- Depreciation
- 32
- 414
- Tax %
- 25
- Net Profit
- 309
- EPS
- 12
- Dividend Payout %
- 16
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
- 1,320
- 738
- Operating Profit
- 770
- OPM %
- 58
- Other Income
- 188
- Interest
- 9
- Depreciation
- 39
- 722
- Tax %
- 23
- Net Profit
- 558
- EPS
- 22
- Dividend Payout %
- 23
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 22
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 22
- 1,330
- 739
- Operating Profit
- 635
- OPM %
- 48
- Other Income
- 45
- Interest
- 13
- Depreciation
- 43
- 579
- Tax %
- 25
- Net Profit
- 433
- EPS
- 17
- Dividend Payout %
- 35
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 17
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 17
- 1,051
- 645
- Operating Profit
- 462
- OPM %
- 44
- Other Income
- 57
- Interest
- 7
- Depreciation
- 55
- 400
- Tax %
- 26
- Net Profit
- 296
- EPS
- 12
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 12
- 1,094
- 731
- Operating Profit
- 417
- OPM %
- 38
- Other Income
- 54
- Interest
- 8
- Depreciation
- 57
- 351
- Tax %
- 23
- Net Profit
- 272
- EPS
- 11
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 11
- 1,907
- 1,567
- Operating Profit
- —
- OPM %
- —
- Other Income
- 44
- Interest
- 18
- Depreciation
- 137
- 245
- Tax %
- 27
- Net Profit
- 178
- EPS
- —
- Dividend Payout %
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- —
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- 6%
- 3 Years:
- -6%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 0%
- 3 Years:
- -21%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -47%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- 26%
- 3 Years:
- 18%
- Last Year:
- 13%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| LIABILITIES | - | - | - | - | - | - | - |
| Equity Capital | 0 | 13 | 25 | 25 | 25 | 25 | 25 |
| 578 | 770 | 1,040 | 1,495 | 1,724 | 2,001 | 2,273 | |
| 83 | 94 | 106 | 67 | 65 | 39 | 70 | |
| Trade Payables | 54 | 71 | 83 | 106 | 67 | 42 | 71 |
| 102 | 282 | 207 | 248 | 222 | 107 | 148 | |
| Total Liabilities | 816 | 1,230 | 1,461 | 1,942 | 2,103 | 2,214 | 2,588 |
| ASSETS | - | - | - | - | - | - | - |
| 271 | 357 | 441 | 534 | 512 | 670 | 685 | |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 253 |
| 7 | 276 | 426 | 600 | 710 | 893 | 1,116 | |
| 157 | 175 | 201 | 283 | 311 | 231 | 154 | |
| 0 | 0 | 0 | 0 | 0 | 134 | 242 | |
| Cash & Bank | 13 | 14 | 10 | 33 | 46 | 22 | 23 |
| 257 | 307 | 286 | 462 | 358 | 86 | 114 | |
| Total Assets | 816 | 1,230 | 1,461 | 1,942 | 2,103 | 2,214 | 2,588 |
| Total Debt | 83 | 185 | 141 | 96 | 69 | 39 | 70 |
| Net Working Capital | 232 | 191 | 345 | 900 | 801 | 1,107 | 495 |
| Contingent Liabilities | 11 | 10 | 6 | 6 | 6 | 18 | 19 |
| Book Value per Share | 0.00 | 61.50 | 41.84 | 59.74 | 68.72 | 79.59 | 90.29 |
| Face Value | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Total Debt | 83 | 185 | 141 | 96 | 69 | 39 | 70 |
| Net Working Capital | 232 | 191 | 345 | 900 | 801 | 1,107 | 495 |
| Contingent Liabilities | 11 | 10 | 6 | 6 | 6 | 18 | 19 |
| Book Value per Share | 0.00 | 61.50 | 41.84 | 59.74 | 68.72 | 79.59 | 90.29 |
| Face Value | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
- Equity Capital
- 0
- 578
- 83
- Trade Payables
- 54
- 102
- Total Liabilities
- 816
- 271
- Capital Work in Progress
- 111
- 7
- 157
- 0
- Cash & Bank
- 13
- 257
- Total Assets
- 816
- Total Debt
- 83
- Net Working Capital
- 232
- Contingent Liabilities
- 11
- Book Value per Share
- 0.00
- Face Value
- 0.00
- Total Debt
- 83
- Net Working Capital
- 232
- Contingent Liabilities
- 11
- Book Value per Share
- 0.00
- Face Value
- 0.00
- Equity Capital
- 13
- 770
- 94
- Trade Payables
- 71
- 282
- Total Liabilities
- 1,230
- 357
- Capital Work in Progress
- 102
- 276
- 175
- 0
- Cash & Bank
- 14
- 307
- Total Assets
- 1,230
- Total Debt
- 185
- Net Working Capital
- 191
- Contingent Liabilities
- 10
- Book Value per Share
- 61.50
- Face Value
- 1.00
- Total Debt
- 185
- Net Working Capital
- 191
- Contingent Liabilities
- 10
- Book Value per Share
- 61.50
- Face Value
- 1.00
- Equity Capital
- 25
- 1,040
- 106
- Trade Payables
- 83
- 207
- Total Liabilities
- 1,461
- 441
- Capital Work in Progress
- 96
- 426
- 201
- 0
- Cash & Bank
- 10
- 286
- Total Assets
- 1,461
- Total Debt
- 141
- Net Working Capital
- 345
- Contingent Liabilities
- 6
- Book Value per Share
- 41.84
- Face Value
- 1.00
- Total Debt
- 141
- Net Working Capital
- 345
- Contingent Liabilities
- 6
- Book Value per Share
- 41.84
- Face Value
- 1.00
- Equity Capital
- 25
- 1,495
- 67
- Trade Payables
- 106
- 248
- Total Liabilities
- 1,942
- 534
- Capital Work in Progress
- 30
- 600
- 283
- 0
- Cash & Bank
- 33
- 462
- Total Assets
- 1,942
- Total Debt
- 96
- Net Working Capital
- 900
- Contingent Liabilities
- 6
- Book Value per Share
- 59.74
- Face Value
- 1.00
- Total Debt
- 96
- Net Working Capital
- 900
- Contingent Liabilities
- 6
- Book Value per Share
- 59.74
- Face Value
- 1.00
- Equity Capital
- 25
- 1,724
- 65
- Trade Payables
- 67
- 222
- Total Liabilities
- 2,103
- 512
- Capital Work in Progress
- 165
- 710
- 311
- 0
- Cash & Bank
- 46
- 358
- Total Assets
- 2,103
- Total Debt
- 69
- Net Working Capital
- 801
- Contingent Liabilities
- 6
- Book Value per Share
- 68.72
- Face Value
- 1.00
- Total Debt
- 69
- Net Working Capital
- 801
- Contingent Liabilities
- 6
- Book Value per Share
- 68.72
- Face Value
- 1.00
- Equity Capital
- 25
- 2,001
- 39
- Trade Payables
- 42
- 107
- Total Liabilities
- 2,214
- 670
- Capital Work in Progress
- 179
- 893
- 231
- 134
- Cash & Bank
- 22
- 86
- Total Assets
- 2,214
- Total Debt
- 39
- Net Working Capital
- 1,107
- Contingent Liabilities
- 18
- Book Value per Share
- 79.59
- Face Value
- 1.00
- Total Debt
- 39
- Net Working Capital
- 1,107
- Contingent Liabilities
- 18
- Book Value per Share
- 79.59
- Face Value
- 1.00
- Equity Capital
- 25
- 2,273
- 70
- Trade Payables
- 71
- 148
- Total Liabilities
- 2,588
- 685
- Capital Work in Progress
- 253
- 1,116
- 154
- 242
- Cash & Bank
- 23
- 114
- Total Assets
- 2,588
- Total Debt
- 70
- Net Working Capital
- 495
- Contingent Liabilities
- 19
- Book Value per Share
- 90.29
- Face Value
- 1.00
- Total Debt
- 70
- Net Working Capital
- 495
- Contingent Liabilities
- 19
- Book Value per Share
- 90.29
- Face Value
- 1.00
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 50 | 359 | 329 | 270 | 493 | 376 | 301 | |
| Cash from Investing | -65 | -367 | -258 | -90 | -237 | -362 | -321 |
| Cash from Financing | 26 | 9 | -76 | -156 | -243 | -40 | 21 |
| 11 | 1 | -4 | 23 | 13 | -26 | 1 | |
| Free Cash Flow | 50 | 259 | 221 | 212 | 339 | 146 | 159 |
| OCF / Net Profit | 0.46 | 1.33 | 1.07 | 0.48 | 1.14 | 1.27 | 1.11 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 | 1,177 | 1,077 |
| OCF / Net Profit | 0.46 | 1.33 | 1.07 | 0.48 | 1.14 | 1.27 | 1.11 |
| Cumulative 5-Year FCF | 0 | 0 | 0 | 0 | 0 | 1,177 | 1,077 |
- 50
- Cash from Investing
- -65
- Cash from Financing
- 26
- 11
- Free Cash Flow
- 50
- OCF / Net Profit
- 0.46
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.46
- Cumulative 5-Year FCF
- 0
- 359
- Cash from Investing
- -367
- Cash from Financing
- 9
- 1
- Free Cash Flow
- 259
- OCF / Net Profit
- 1.33
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.33
- Cumulative 5-Year FCF
- 0
- 329
- Cash from Investing
- -258
- Cash from Financing
- -76
- -4
- Free Cash Flow
- 221
- OCF / Net Profit
- 1.07
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.07
- Cumulative 5-Year FCF
- 0
- 270
- Cash from Investing
- -90
- Cash from Financing
- -156
- 23
- Free Cash Flow
- 212
- OCF / Net Profit
- 0.48
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.48
- Cumulative 5-Year FCF
- 0
- 493
- Cash from Investing
- -237
- Cash from Financing
- -243
- 13
- Free Cash Flow
- 339
- OCF / Net Profit
- 1.14
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 1.14
- Cumulative 5-Year FCF
- 0
- 376
- Cash from Investing
- -362
- Cash from Financing
- -40
- -26
- Free Cash Flow
- 146
- OCF / Net Profit
- 1.27
- Cumulative 5-Year FCF
- 1,177
- OCF / Net Profit
- 1.27
- Cumulative 5-Year FCF
- 1,177
- 301
- Cash from Investing
- -321
- Cash from Financing
- 21
- 1
- Free Cash Flow
- 159
- OCF / Net Profit
- 1.11
- Cumulative 5-Year FCF
- 1,077
- OCF / Net Profit
- 1.11
- Cumulative 5-Year FCF
- 1,077
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| PER SHARE | - | - | - | - | - | - | - |
| EPS (₹) | 0.00 | 21.22 | 12.12 | 21.92 | 16.99 | 11.64 | 10.67 |
| Book Value (₹) | 0.00 | 61.50 | 41.84 | 59.74 | 68.72 | 79.59 | 90.29 |
| Dividend per Share (₹) | 0.00 | 5.00 | 2.00 | 5.00 | 6.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 0.00 | 11.53 | 13.37 | 23.46 | 18.69 | 13.79 | 12.92 |
| PROFITABILITY | - | - | - | - | - | - | - |
| Operating Margin % | 45.56% | 48.32% | 45.29% | 58.29% | 47.72% | 38.60% | 33.16% |
| Net Margin % | 28.92% | 32.39% | 30.57% | 42.24% | 32.50% | 28.20% | 24.85% |
| ROE % | 18.92% | 39.71% | 33.40% | 43.17% | 26.46% | 15.70% | 12.56% |
| ROCE % | 23.87% | 46.23% | 39.15% | 51.79% | 34.48% | 20.99% | 16.14% |
| 13.39% | 26.40% | 22.94% | 32.80% | 21.39% | 13.74% | 11.32% | |
| EFFICIENCY | - | - | - | - | - | - | - |
| Debtor Days | 142 | 58 | 40 | 47 | 47 | 42 | 63 |
| Inventory Days | 152 | 73 | 68 | 67 | 82 | 94 | 64 |
| Payable Days | 193 | 101 | 94 | 87 | 80 | 64 | 70 |
| 102 | 30 | 13 | 26 | 49 | 72 | 57 | |
| FINANCIAL HEALTH | - | - | - | - | - | - | - |
| Debt to Equity (x) | 0.14x | 0.24x | 0.13x | 0.06x | 0.04x | 0.02x | 0.03x |
| Interest Coverage (x) | 57.60x | 17.39x | 36.49x | 85.72x | 46.45x | 54.75x | 44.92x |
| 2.22x | 1.60x | 2.07x | 3.60x | 3.68x | 10.45x | 3.32x | |
| GROWTH | - | - | - | - | - | - | - |
| Revenue Growth % | 0.00% | 120.68% | 21.10% | 30.75% | 0.75% | -20.96% | 4.01% |
| Operating Profit Growth % | 0.00% | 134.04% | 13.49% | 68.40% | -17.51% | -27.20% | -9.93% |
| Net Profit Growth % | 0.00% | 147.16% | 14.28% | 80.82% | -22.49% | -31.47% | -8.35% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31.48% | -8.35% | |
| VALUATION | - | - | - | - | - | - | - |
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 58.10x | 108.68x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 8.50x | 12.85x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 37.28x | 71.00x |
- EPS (₹)
- 0.00
- Book Value (₹)
- 0.00
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 0.00
- Operating Margin %
- 45.56%
- Net Margin %
- 28.92%
- ROE %
- 18.92%
- ROCE %
- 23.87%
- 13.39%
- Debtor Days
- 142
- Inventory Days
- 152
- Payable Days
- 193
- 102
- Debt to Equity (x)
- 0.14x
- Interest Coverage (x)
- 57.60x
- 2.22x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
- EPS (₹)
- 21.22
- Book Value (₹)
- 61.50
- Dividend per Share (₹)
- 5.00
- Cash EPS (₹)
- 11.53
- Operating Margin %
- 48.32%
- Net Margin %
- 32.39%
- ROE %
- 39.71%
- ROCE %
- 46.23%
- 26.40%
- Debtor Days
- 58
- Inventory Days
- 73
- Payable Days
- 101
- 30
- Debt to Equity (x)
- 0.24x
- Interest Coverage (x)
- 17.39x
- 1.60x
- Revenue Growth %
- 120.68%
- Operating Profit Growth %
- 134.04%
- Net Profit Growth %
- 147.16%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
- EPS (₹)
- 12.12
- Book Value (₹)
- 41.84
- Dividend per Share (₹)
- 2.00
- Cash EPS (₹)
- 13.37
- Operating Margin %
- 45.29%
- Net Margin %
- 30.57%
- ROE %
- 33.40%
- ROCE %
- 39.15%
- 22.94%
- Debtor Days
- 40
- Inventory Days
- 68
- Payable Days
- 94
- 13
- Debt to Equity (x)
- 0.13x
- Interest Coverage (x)
- 36.49x
- 2.07x
- Revenue Growth %
- 21.10%
- Operating Profit Growth %
- 13.49%
- Net Profit Growth %
- 14.28%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
- EPS (₹)
- 21.92
- Book Value (₹)
- 59.74
- Dividend per Share (₹)
- 5.00
- Cash EPS (₹)
- 23.46
- Operating Margin %
- 58.29%
- Net Margin %
- 42.24%
- ROE %
- 43.17%
- ROCE %
- 51.79%
- 32.80%
- Debtor Days
- 47
- Inventory Days
- 67
- Payable Days
- 87
- 26
- Debt to Equity (x)
- 0.06x
- Interest Coverage (x)
- 85.72x
- 3.60x
- Revenue Growth %
- 30.75%
- Operating Profit Growth %
- 68.40%
- Net Profit Growth %
- 80.82%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
- EPS (₹)
- 16.99
- Book Value (₹)
- 68.72
- Dividend per Share (₹)
- 6.00
- Cash EPS (₹)
- 18.69
- Operating Margin %
- 47.72%
- Net Margin %
- 32.50%
- ROE %
- 26.46%
- ROCE %
- 34.48%
- 21.39%
- Debtor Days
- 47
- Inventory Days
- 82
- Payable Days
- 80
- 49
- Debt to Equity (x)
- 0.04x
- Interest Coverage (x)
- 46.45x
- 3.68x
- Revenue Growth %
- 0.75%
- Operating Profit Growth %
- -17.51%
- Net Profit Growth %
- -22.49%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 0.00x
- EPS (₹)
- 11.64
- Book Value (₹)
- 79.59
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 13.79
- Operating Margin %
- 38.60%
- Net Margin %
- 28.20%
- ROE %
- 15.70%
- ROCE %
- 20.99%
- 13.74%
- Debtor Days
- 42
- Inventory Days
- 94
- Payable Days
- 64
- 72
- Debt to Equity (x)
- 0.02x
- Interest Coverage (x)
- 54.75x
- 10.45x
- Revenue Growth %
- -20.96%
- Operating Profit Growth %
- -27.20%
- Net Profit Growth %
- -31.47%
- -31.48%
- P/E (x)
- 58.10x
- P/B (x)
- 8.50x
- Dividend Yield %
- 0.00%
- 37.28x
- EPS (₹)
- 10.67
- Book Value (₹)
- 90.29
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 12.92
- Operating Margin %
- 33.16%
- Net Margin %
- 24.85%
- ROE %
- 12.56%
- ROCE %
- 16.14%
- 11.32%
- Debtor Days
- 63
- Inventory Days
- 64
- Payable Days
- 70
- 57
- Debt to Equity (x)
- 0.03x
- Interest Coverage (x)
- 44.92x
- 3.32x
- Revenue Growth %
- 4.01%
- Operating Profit Growth %
- -9.93%
- Net Profit Growth %
- -8.35%
- -8.35%
- P/E (x)
- 108.68x
- P/B (x)
- 12.85x
- Dividend Yield %
- 0.00%
- 71.00x
Documents
Announcements
- Credit Rating- Others
2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others
- Analysts/Institutional Investor Meet/Con. Call Updates
2026-08-11 - Cohance Lifesciences Limited has informed the Exchange about Transcript
Annual Reports
Credit Ratings
- Credit Rating- Others
2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others
- Credit Rating
2025-12-03 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating
- Credit Rating
2025-08-27 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating
Concalls
May 2026
Feb 2026
Nov 2025

